Efficacy and safety at 96 weeks of bulevirtide 2 mg or 10 mg monotherapy for chronic hepatitis delta: results from an interim analysis of a phase 3 randomized studyHeiner Wedemeyer,Soo Aleman,Maurizia Brunetto,Antje Blank,Pietro Andreone,Pavel Bogomolov,Vladimir Chulanov,Nina Mamonova,Natalia Geyvandova,Viacheslav Morozov,Olga Sagalova,Tatyana Stepanova,Dmitry Manuilov,Renee-Claude Mercier,Qi An,John Flaherty,Anu Osinusi,Audrey Lau,Julian Schulze zur Wiesch,Markus Cornberg,Stefan Zeuzem,Pietro LamperticoGUT（2023）引用 0|浏览1暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
